RPID
Rapid Micro Biosystems, Inc.3.5200
+0.0500+1.44%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Key Stats
Market Cap
156.02MP/E (TTM)
-Basic EPS (TTM)
-1.00Dividend Yield
0%Recent Filings
8-K
Record Q4 revenue surges 37%
Rapid Micro Biosystems posted record Q4 2025 revenue of ~$11.3 million, up 37% year-over-year, fueled by a landmark multi-system order from a top-20 global biopharma customer. Full-year revenue hit ~$33.6 million, growing 20%, with recurring revenue up 15% to ~$17.8 million after placing 28 new Growth Direct systems. Record results beat raised guidance.
8-K
Q3 revenue up, raises guidance
Rapid Micro Biosystems posted Q3 revenue of $7.8 million, up 3% from last year, with recurring revenue surging 32% to $4.8 million on record consumables. Gross margin edged to 9%. Record multi-system order from a top-20 biopharma spans North America, Europe, Asia Pacific. Raised 2025 revenue guidance to at least $33.0 million, assuming 27 system placements. Cash sits at ~$42 million.
10-Q
Q3 FY2025 results
Rapid Micro Biosystems posted Q3 revenue of $7.8M, up 3.1% y/y but flat q/q (derived), with recurring revenue jumping 31.7% y/y to $4.8M on stronger consumables and services while systems dipped to 5 placements. Gross margins held positive amid cost controls, narrowing operating loss to $11.4M from $12.0M y/y; diluted EPS steady at -$0.26 on 45.0M shares. Cash plus short-term investments stood at $41.2M after drawing $20M term loan (11.5% rate, matures 2030) from Trinity Capital in August. Debt covenants bind flexibility. Systems validation lags placements. Competition threatens recurring revenue ramp.
8-K
Secures $45M loan, draws $20M
Rapid Micro Biosystems closed a $45M five-year term loan on August 8, 2025, drawing $20M upfront at 11.5% interest with a 36-month interest-only period and no revenue covenants. Q2 revenue hit $7.3M, up 10% year-over-year, with gross margin turning positive at 4%. Cash stands at $32M. Future tranches hinge on milestones.
10-Q
Q2 FY2025 results
Rapid Micro Biosystems posted Q2 revenue up 9.7% y/y to $7.3M (derived), with product revenue +5.8% y/y to $4.8M and service revenue +18.2% y/y to $2.5M, while recurring revenue climbed 15.0% y/y to $4.4M. Losses narrowed sharply, operating loss -12.1M (-9.2% y/y) and net loss -11.9M (-5.7% y/y), with EPS improving to -$0.27 from -$0.29 y/y; net loss exceeded operating loss due to minimal interest income and taxes. Cash burn eased, operating cash use -18.8M (-26.8% y/y) for H1, ending with $18.3M cash plus $12.9M short-term investments; post-quarter, drew $20M under a $45M LSA with Trinity Capital (maturing 2030 at ~11.5%, warrants issued). Cumulative systems placed hit 169. Delisting from Nasdaq remains a risk.
IPO
Employees
Sector
Industry
BIO
Bio-Rad Laboratories, Inc.
302.02-5.90
BRKR
Bruker Corporation
44.96-0.71
CODX
Co-Diagnostics, Inc.
0.25-0.02
INBS
Intelligent Bio Solutions Inc.
5.50+0.00
LUCD
Lucid Diagnostics Inc.
1.12+0.01
MASS
908 Devices Inc.
5.78-0.13
PACB
Pacific Biosciences of Californ
2.02-0.10
RMD
ResMed Inc.
247.34-5.73
RMSL
RemSleep Holdings, Inc.
0.00+0.00
STE
STERIS plc (Ireland)
253.03-1.04